AG-858

DB05502InvestigationalProtein Based Therapies

AG-858 (autologous heat-shock protein 70 peptide vaccine) is a recombinant cancer vaccine made with tumor-derived heat shock protein 70 (HSP70) peptide complexes. HSP70 associates with antigenic peptides, transporting them into... Tumor-derived HSP70-peptide complexes used in vaccine preparations have been shown to prime tumor immunity and tumor-specific T cells in animal models.

Mechanism
Curator reviewed
Primary indication
Investigated for use/treatment in leukemia (myeloid).Curator reviewed
Code names
AG-858

Resolves to

What you can answer from here — as of July 03, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
1Clinical trialPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which drugs share a target with AG-858, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account